(Q24250187)

26 June 2017

0 references

1 reference

title

Kava extract versus placebo for treating anxiety (English)

0 references

Kava extract for treating anxiety (English)

1 reference

26 June 2017

0 references

0 references

2

Edzard Ernst

0 references

author name string

Max H Pittler

1

0 references

M H Pittler

1

1 reference

26 June 2017

E Edzard

2

1 reference

26 June 2017

E Ernst

2

0 references

language of work or name

English

0 references

publication date

20 January 2003

0 references

1 January 2001

1 reference

Cochrane Database of Systematic Reviews

26 June 2017

2002

0 references

published in

1 reference

26 June 2017

4

1 reference

26 June 2017

2

0 references

page(s)

CD003383

1 reference

A placebo-controlled study of Kava kava in generalized anxiety disorder

26 June 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Kava treatment in patients with anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Evaluation of combining kava extract with hormone replacement therapy in the treatment of postmenopausal anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

The efficacy of Cavain in patients suffering from anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin - A double-blind placebo-controlled study of four weeks treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Why patients use alternative medicine: results of a national study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Association of road-traffic accidents with benzodiazepine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Psychoactive substances of the South Seas: betel, kava and pituri

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Publication bias in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Language bias in randomised controlled trials published in English and German.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Bias in location and selection of studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Alternative therapy bias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

The use of complementary and alternative therapies to treat anxiety and depression in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Six-month prevalence of psychiatric disorders in three communities 1980 to 1982.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Bias against European journals in medical publication Databases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Efficacy of kava extract for treating anxiety: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Location bias in controlled clinical trials of complementary/alternative therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

A systematic review of the safety of kava extract in the treatment of anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Kava extracts: safety and risks including rare hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

Benzodiazepines and driver safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

7 January 2021

Adverse-effect profile of kava

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

7 January 2021

Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

7 January 2021

Toxicity of kava pyrones, drug safety and precautions--a case study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

7 January 2021

The economic burden of anxiety disorders in the 1990s.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003383

7 January 2021

10.1002/14651858.CD003383

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

583605

26 June 2017

583605

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

0 references

1 reference

583605

1 reference